<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560804</url>
  </required_header>
  <id_info>
    <org_study_id>100</org_study_id>
    <nct_id>NCT03560804</nct_id>
  </id_info>
  <brief_title>Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs</brief_title>
  <official_title>Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of the study is to determine whether the hemodynamic parameters measured&#xD;
      with the two methods -impedance cardiography and applanation tonometry- can be predictive of&#xD;
      the antihypertensive effect of two different classes of drugs, ATII antagonists and&#xD;
      diuretics.&#xD;
&#xD;
      The drugs that will be used in the study are olmesartan and chlorthalidone and the duration&#xD;
      of the study is 12 months.&#xD;
&#xD;
      The other basic aim of the study is to determine whether there is a difference (&gt;6mmHg)&#xD;
      between the two drugs regarding the reduction of the mean 24hour blood pressure and the&#xD;
      effect of them on the hemodynamic parameters.&#xD;
&#xD;
      The hemodynamic parameters that will be measured by applanation tonometry are augmentation&#xD;
      index, central blood pressure and pulse wave velocity.&#xD;
&#xD;
      The hemodynamic parameters that will be measured by impedance cardiography are cardiac index,&#xD;
      thoracic fluid content index, systemic vascular resistance index and others.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal aim of the study is to determine whether the hemodynamic parameters measured&#xD;
      with the two methods -impedance cardiography and applanation tonometry- can be predictive of&#xD;
      the antihypertensive effect of two different classes of drugs, ATII antagonists and&#xD;
      diuretics.&#xD;
&#xD;
      The drugs that will be used in the study are olmesartan and chlorthalidone and the duration&#xD;
      of the study is 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2014</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by Sphygmocor devive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic vascular resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by impendance cardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Daytime and nighttime systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Arterial Stiffness</condition>
  <condition>Ambulatory Blood Pressure Monitoring</condition>
  <arm_group>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.</description>
    <arm_group_label>Olmesartan</arm_group_label>
    <other_name>Olartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <other_name>Hygroton</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Drug naive patients with 1st or 2nd grade Arterial Hypertension according to the&#xD;
             ESH/ESC guidelines 2013&#xD;
&#xD;
          -  The patient has signed the concent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary Hypertension&#xD;
&#xD;
          -  3rd grade of Arterial Hypertension&#xD;
&#xD;
          -  Chronic renal failure&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Sleep apnea syndrome&#xD;
&#xD;
          -  Chronic or acute inflammatory diseases&#xD;
&#xD;
          -  Stroke, myocardial infarction, angina pectoris in the past 6 months&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Neoplasms&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Valvular Heart disease&#xD;
&#xD;
          -  Heigt &lt; 120cm or &gt; 230cm, Weight &lt;30kg or &gt;155kg&#xD;
&#xD;
          -  Heart Arrhytmias&#xD;
&#xD;
          -  Artificial cardiac pacemaker&#xD;
&#xD;
          -  Hemodymanic unstable patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zebekakis Pantelis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hypertension Excellence Center, 1st Department of Internal Medicine, AHEPA University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hypertension Excellence Center, AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54635</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>June 15, 2018</last_update_submitted>
  <last_update_submitted_qc>June 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Pikilidou, MD, MSc, PhD</investigator_full_name>
    <investigator_title>Post-doctoral researcher</investigator_title>
  </responsible_party>
  <keyword>olmesartan</keyword>
  <keyword>chlorthalidone</keyword>
  <keyword>hemodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

